表紙
市場調查報告書
商品編碼
997349

市場焦點:多囊性卵巢症候群(PCOS)

Market Spotlight: Polycystic Ovary Syndrome (PCOS)

出版日期: | 出版商: Datamonitor Healthcare | 英文 27 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球15∼49歲的女性中多囊性卵巢症候群(PCOS)罹患數量估計從2019年約1億1,350萬件(NIH標準)到1億8,780萬件(鹿特丹標準),其數從1億2,020件(NIH標準)預計增加到1億9,780萬(鹿特丹標準)。

在PCOS領域認證的藥物,以雌激素受體1,雄激素受體,濾泡刺激素受體為標的。這些藥經由口服、皮下,以及肌肉內的途徑施用。

PCOS的開發平台唯一可利用的治療方法,是以促性腺激素分泌放出荷爾蒙受體為標的。口服給藥。I期內分泌的認證的整體可能性是9.7%,藥物從III期進行的平均概率是67.7%。藥物,從I期到內分泌領域全體認證平均花費9.6年。

本市場焦點報告,含括多囊性卵巢症候群(PCOS)市場,提供主要的成藥與開發平台藥物,臨床試驗,成功的概率,及10年的疾病盛行率預測等資訊。

目錄

內容

概要

重要的要點

疾病背景

治療

  • Clomiphene citrate
  • 促性腺激素分泌
  • 抗糖尿病藥物
  • 芳香酶抑制劑
  • 抗雄激素
  • 口服避孕藥

流行病學

成藥

開發平台藥物

成功概率

臨床試驗情勢

  • 各狀態的贊助商
  • 各階段的贊助商

參考文件

附錄

圖的清單

表格的清單

目錄
Product Code: DMKC0182769

This Market Spotlight report covers the Polycystic Ovary Syndrome (PCOS) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease prevalence forecast.

Key Takeaways:

Datamonitor Healthcare estimates that in 2019, there were approximately 113.5 million (NIH criteria) to 187.8 million (Rotterdam criteria) prevalent cases of polycystic ovary syndrome (PCOS) in females aged 15-49 years worldwide, and expects that number to increase to between 120.2 million (NIH criteria) and 197.8 million (Rotterdam criteria) by 2028.

The approved drugs in the PCOS space target estrogen receptor 1, androgen receptor, and follicle stimulating hormone receptor. These drugs are administered via the oral, subcutaneous, or intramuscular routes.

The only therapy available in the pipeline for PCOS targets gonadotropin-releasing hormone receptor. It is administered orally. The overall likelihood of approval of a Phase I endocrine asset is 9.7%, and the average probability a drug advances from Phase III is 67.7%. Drugs, on average, take 9.6 years from Phase I to approval in the overall endocrine space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for PCOS have been in the late phases of development, with 81% of trials in Phase III-IV, and only 19% in Phase I-II.

The US has the highest number of PCOS clinical trials globally. Germany and the UK lead the major European markets, while China, Indonesia, and South Korea share the top spot in Asia.

Clinical trial activity in the PCOS space is dominated by completed trials. Merck KGaA has the highest number of completed clinical trials for PCOS, with five trials.

Merck KGaA leads industry sponsors with the highest overall number of clinical trials for PCOS, followed by AstraZeneca and Merck & Co.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Clomiphene citrate
  • Gonadotropins
  • Antidiabetic agents
  • Aromatase inhibitors
  • Anti-androgens
  • Oral contraceptive pills

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

PROBABILITY OF SUCCESS

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of PCOS (Rotterdam Criteria), 2019-28
  • Figure 2: Trends in prevalent cases of PCOS (NIH Criteria), 2019-28
  • Figure 3: Probability of success in the endocrine pipeline
  • Figure 4: Clinical trials in PCOS
  • Figure 5: Top 10 drugs for clinical trials in PCOS
  • Figure 6: Top 10 companies for clinical trials in PCOS
  • Figure 7: Trial locations in PCOS
  • Figure 8: PCOS trials status
  • Figure 9: PCOS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of PCOS (Rotterdam Criteria), 2019-28
  • Table 2: Prevalent cases of PCOS (NIH Criteria), 2019-28
  • Table 3: Marketed drugs for PCOS
  • Table 4: Pipeline drugs for PCOS in the US